Mesenchymal stem cells (MSCs) have been extensively used in the field of tissue engineering as a source of smooth muscle cells (SMCs). However, recent studies showed deficits in the contractile function of SMCs derived from senescent MSCs and there are no available strategies to restore the contractile function that is impaired due to cellular or organismal senescence. In this study, we developed a tetracycline-regulatable system and employed micropost tissue arrays to evaluate the effects of the embryonic transcription factor, NANOG, on the contractility of senescent MSCs. Using this system, we show that expression of NANOG fortified the actin cytoskeleton and restored contractile function that was impaired in senescent MSCs. NANOG increased the expression of smooth muscle α-actin (ACTA2) as well as the contractile force generated by cells in three-dimensional microtissues. Interestingly, NANOG worked together with transforming growth factor-beta1 to further enhance the contractility of senescent microtissues. The effect of NANOG on contractile function was sustained for about 10 days after termination of its expression. Our results show that NANOG could reverse the effects of stem cell senescence and restore the myogenic differentiation potential of senescent MSCs. These findings may enable development of novel strategies to restore the function of senescent cardiovascular and other SMC-containing tissues.
Get full access to this article
View all access options for this article.
References
1.
AlagesanS., and GriffinM.D.Autologous and allogeneic mesenchymal stem cells in organ transplantation: what do we know about their safety and efficacy? Curr Opin Organ Transplant, 19, 65, 2014.
2.
GriffinM.D., EllimanS.J., CahillE., EnglishK., CeredigR., and RitterT.Concise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots? Stem Cells, 31, 2033, 2013.
3.
MalgieriA., KantzariE., PatriziM.P., and GambardellaS.Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. Int J Clin Exp Med, 3, 248, 2010.
4.
Meirelles LdaS., and NardiN.B. Methodology, biology and clinical applications of mesenchymal stem cells. Front Biosci, 14, 4281, 2009.
5.
StenderupK., JustesenJ., ClausenC., and KassemM.Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone, 33, 919, 2003.
6.
BaxterM.A., WynnR.F., JowittS.N., WraithJ.E., FairbairnL.J., and BellantuonoI.Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells, 22, 675, 2004.
7.
HaciaJ.G., LeeC.C., JimenezD.F., KaramanM.W., HoV.V., SiegmundK.D., and TarantalA.F.Age-related gene expression profiles of rhesus monkey bone marrow-derived mesenchymal stem cells. J Cell Biochem, 103, 1198, 2008.
8.
HanJ., LiuJ.Y., SwartzD.D., and AndreadisS.T.Molecular and functional effects of organismal ageing on smooth muscle cells derived from bone marrow mesenchymal stem cells. Cardiovasc Res, 87, 147, 2010.
9.
ScruggsB.A., SemonJ.A., ZhangX., ZhangS., BowlesA.C., PandeyA.C., ImhofK.M., KalueffA.V., GimbleJ.M., and BunnellB.A.Age of the donor reduces the ability of human adipose-derived stem cells to alleviate symptoms in the experimental autoimmune encephalomyelitis mouse model. Stem Cells Transl Med, 2, 797, 2013.
10.
WagnerW., HornP., CastoldiM., DiehlmannA., BorkS., SaffrichR., BenesV., BlakeJ., PfisterS., EcksteinV., and HoA.D.Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One, 3, e2213, 2008.
11.
BonabM.M., AlimoghaddamK., TalebianF., GhaffariS.H., GhavamzadehA., and NikbinB.Aging of mesenchymal stem cell in vitro. BMC Cell Biol, 7, 14, 2006.
12.
WheelerJ.B., MukherjeeR., StroudR.E., JonesJ.A., and IkonomidisJ.S.Relation of murine thoracic aortic structural and cellular changes with aging to passive and active mechanical properties. J Am Heart Assoc, 4, e001744, 2015.
13.
RagnauthC.D., WarrenD.T., LiuY., McNairR., TajsicT., FiggN., ShroffR., SkepperJ., and ShanahanC.M.Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation, 121, 2200, 2010.
14.
MatthewsC., GorenneI., ScottS., FiggN., KirkpatrickP., RitchieA., GoddardM., and BennettM.Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Circ Res, 99, 156, 2006.
15.
SaphirsteinR.J., and MorganK.G.The contribution of vascular smooth muscle to aortic stiffness across length scales. Microcirculation, 21, 201, 2014.
16.
ZiemanS.J., MelenovskyV., and KassD.A.Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol, 25, 932, 2005.
17.
WangM., JiangL., MonticoneR.E., and LakattaE.G.Proinflammation: the key to arterial aging. Trends Endocrinol Metab, 25, 72, 2014.
18.
DavisR., PillaiS., LawrenceN., SebtiS., and ChellappanS.P.TNF-alpha-mediated proliferation of vascular smooth muscle cells involves Raf-1-mediated inactivation of Rb and transcription of E2F1-regulated genes. Cell Cycle, 11, 109, 2012.
19.
GoetzeS., XiX.P., KawanoY., KawanoH., FleckE., HsuehW.A., and LawR.E.TNF-alpha-induced migration of vascular smooth muscle cells is MAPK dependent. Hypertension, 33, 183, 1999.
20.
ManeaA., ManeaS.A., GafencuA.V., RaicuM., and SimionescuM.AP-1-dependent transcriptional regulation of NADPH oxidase in human aortic smooth muscle cells: role of p22phox subunit. Arterioscler Thromb Vasc Biol, 28, 878, 2008.
21.
BajpaiV.K., and AndreadisS.T.Stem cell sources for vascular tissue engineering and regeneration. Tissue Eng Part B Rev, 18, 405, 2012.
22.
CaplanA.I.Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol, 213, 341, 2007.
23.
PengH.-F., LiuJ.Y., AndreadisS.T., and SwartzD.D.Hair follicle-derived smooth muscle cells and small intestinal submucosa for engineering mechanically robust and vasoreactive vascular media. Tissue Eng Part A, 17, 981, 2011.
24.
MistriotisP., and AndreadisS.T.Hair follicle: a novel source of multipotent stem cells for tissue engineering and regenerative medicine. Tissue Eng Part B Rev, 19, 265, 2013.
25.
HanJ., MistriotisP., LeiP., WangD., LiuS., and AndreadisS.T.Nanog reverses the effects of organismal aging on mesenchymal stem cell proliferation and myogenic differentiation potential. Stem cells (Dayton, Ohio), 30, 2746, 2012.
26.
DoJ.T., and SchölerH.R.Regulatory circuits underlying pluripotency and reprogramming. Trends Pharmacol Sci, 30, 296, 2009.
27.
LegantW.R., PathakA., YangM.T., DeshpandeV.S., McMeekingR.M., and ChenC.S.Microfabricated tissue gauges to measure and manipulate forces from 3D microtissues. Proc Natl Acad Sci, 106, 10097, 2009.
28.
BajpaiV.K., MistriotisP., and AndreadisS.T.Clonal multipotency and effect of long-term in vitro expansion on differentiation potential of human hair follicle derived mesenchymal stem cells. Stem Cell Res, 8, 74, 2012.
29.
BajajB., LeiP., and AndreadisS.T.High efficiencies of gene transfer with immobilized recombinant retrovirus: kinetics and optimization. Biotechnol Prog, 17, 587, 2001.
30.
MistriotisP., BajpaiV.K., WangX., RongN., ShahiniA., AsmaniM., LiangM.-S., WangJ., LeiP., LiuS., ZhaoR., and AndreadisS.T.NANOG reverses the myogenic differentiation potential of senescent stem cells by restoring ACTIN filamentous organization and SRF-dependent gene expression. Stem Cells, 2017; 35:207–221.
31.
PadmashaliR.M., MistriotisP., LiangM.S., and AndreadisS.T.Lentiviral arrays for live-cell dynamic monitoring of gene and pathway activity during stem cell differentiation. Mol Ther, 22, 1971, 2014.
32.
WangD., ParkJ.S., ChuJ.S., KrakowskiA., LuoK., ChenD.J., and LiS.Proteomic profiling of bone marrow mesenchymal stem cells upon transforming growth factor beta1 stimulation. J Biol Chem, 279, 43725, 2004.
33.
KinnerB., ZaleskasJ.M., and SpectorM.Regulation of smooth muscle actin expression and contraction in adult human mesenchymal stem cells. Exp Cell Res, 278, 72, 2002.
34.
LiuJ.Y., PengH.F., GopinathS., TianJ., and AndreadisS.T.Derivation of functional smooth muscle cells from multipotent human hair follicle mesenchymal stem cells. Tissue Eng Part A, 16, 2553, 2010.
35.
OlsonE.N., and NordheimA.Linking actin dynamics and gene transcription to drive cellular motile functions. Nat Rev Mol Cell Biol, 11, 353, 2010.
36.
DehghanifardA., ShahjahaniM., SoleimaniM., and SakiN.The emerging role of mesenchymal stem cells in tissue engineering. Int J Hematol Oncol Stem Cell Res, 7, 46, 2013.
LiuJ.Y., PengH.F., and AndreadisS.T.Contractile smooth muscle cells derived from hair-follicle stem cells. Cardiovasc Res, 79, 24, 2008.
39.
WangC., YinS., CenL., LiuQ., LiuW., CaoY., and CuiL.Differentiation of adipose-derived stem cells into contractile smooth muscle cells induced by transforming growth factor-beta1 and bone morphogenetic protein-4. Tissue Eng Part A, 16, 1201, 2010.
40.
LiangM.S., and AndreadisS.T.Engineering fibrin-binding TGF-beta1 for sustained signaling and contractile function of MSC based vascular constructs. Biomaterials, 32, 8684, 2011.
41.
AlimpertiS., YouH., GeorgeT., AgarwalS.K., and AndreadisS.T.Cadherin-11 regulates both mesenchymal stem cell differentiation into smooth muscle cells and the development of contractile function in vivo. J Cell Sci, 127, 2627, 2014.
RiehlB.D., ParkJ.-H., KwonI.K., and LimJ.Y.Mechanical stretching for tissue engineering: two-dimensional and three-dimensional constructs. Tissue Eng Part B Rev, 18, 288, 2012.
44.
KoobatianM.T., LiangM.S., SwartzD.D., and AndreadisS.T.Differential effects of culture senescence and mechanical stimulation on the proliferation and leiomyogenic differentiation of MSC from different sources: implications for engineering vascular grafts. Tissue Eng Part A, 21, 1364, 2015.
45.
LodishH, BerkA., ZipurskyS.L., et al.Molecular Cell Biology. New York: W.H. Freeman; 2000.
46.
AguilarH.N., and MitchellB.F.Physiological pathways and molecular mechanisms regulating uterine contractility. Hum Reprod Update, 16, 725, 2010.
47.
DuJ., WangX., MierelesC., BaileyJ.L., DebigareR., ZhengB., PriceS.R., and MitchW.E.Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest, 113, 115, 2004.
48.
KongJ.Y., and RabkinS.W.Cytoskeletal actin degradation induced by lovastatin in cardiomyocytes is mediated through caspase-2. Cell Biol Int, 28, 781, 2004.
49.
HuangJ., and ForsbergN.E.Role of calpain in skeletal-muscle protein degradation. Proc Natl Acad Sci U S A, 95, 12100, 1998.
50.
PolgeC., HengA.E., JarzaguetM., VentadourS., ClaustreA., CombaretL., BechetD., MatondoM., Uttenweiler-JosephS., MonsarratB., AttaixD., and TaillandierD.Muscle actin is polyubiquitinylated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1. Faseb J, 25, 3790, 2011.
51.
SolomonV., and GoldbergA.L.Importance of the ATP-ubiquitin-proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts. J Biol Chem, 271, 26690, 1996.
52.
MahfouzW., ElsalmyS., CorcosJ., and FayedA.S.Fundamentals of bladder tissue engineering. Afr J Urol, 19, 51, 2013.
53.
LiangM.-S., KoobatianM., LeiP., SwartzD.D., and AndreadisS.T.Differential and synergistic effects of mechanical stimulation and growth factor presentation on vascular wall function. Biomaterials, 34, 7281, 2013.
54.
YaoL., SwartzD.D., GuginoS.F., RussellJ.A., and AndreadisS.T.Fibrin-based tissue-engineered blood vessels: differential effects of biomaterial and culture parameters on mechanical strength and vascular reactivity. Tissue Eng, 11, 991, 2005.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
